Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Mustafa Cakirca, Cumali Karatoprak, Mehmet Zorlu, Muharrem Kiskac, Mustafa Kanat, Mehmet Ali Cikrikcioglu, Pinar Soysal, Mehmet Hursitoglu, Ahmet Adil Camli, Reha Erkoc, Muhammad Abdulghani

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation.

Original languageEnglish
Pages (from-to)239-243
Number of pages5
JournalDrug Design, Development and Therapy
Volume8
DOIs
Publication statusPublished - 14 Feb 2014

Keywords

  • Asymmetric Dimethylarginine (ADMA)
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Type 2 diabetes mellitus
  • Vildagliptin

Fingerprint Dive into the research topics of 'Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients'. Together they form a unique fingerprint.

Cite this